In a recent study published in Journal of the American Society of Nephrology, a third COVID-19 mRNA vaccine dose in adults with kidney failure who were on dialysis enhanced patients’ protection against SARS-CoV-2 infection during the omicron-dominant period. A patient’s response to vaccination or prior infection—as measured by circulating anti-SARS-CoV-2 antibody levels—was also an important predictor for subsequent risk of infection.
In the study of randomly-selected patients receiving dialysis in the United States, a team led by Shuchi Anand, MD, MS, Pablo Garcia, MD, MS, and Maria Montez Rath, Ph.D. (Stanford University School of Medicine) followed patients’ monthly anti–SARS-CoV-2 antibody levels and ascertained COVID-19 infection during the omicron- dominant period of December 25, 2021 to January 31, 2022 using electronic health records.
Among 3,576 patients receiving dialysis, 901 (25%) received a third mRNA vaccine dose as of December 1, 2022, and early antibody responses to third doses were robust. During the omicron-dominant period, SARS-CoV-2 infection was documented in 340 (7%) patients. Risk for infection was doubled among patients without vaccination and nearly 1.5-fold higher with 1–2 doses compared with 3 doses. Irrespective of vaccine doses, risk for infection was at least 2-fold higher among patients with low circulating levels of anti–SARS-CoV-2 antibodies.
“The COVID-19 pandemic continues to evolve, and it is clear that COVID-19 will become an endemic infection—that is, an infection that circulates at regular intervals in our community. In such a situation, it is critical to devise strategies that protect the most medically vulnerable persons with appropriate vaccine doses or additional preventive measures (such as monoclonal antibodies), and early treatments,” said Dr. Anand. “Measuring a person’s circulating antibody response to SARS-CoV-2 virus may help us identify the highest risk persons eligible for enhanced protection among patients on dialysis, and other immunocompromised or frail populations.”
SARS-CoV-2 infection during the Omicron surge among patients receiving dialysis: the role of circulating receptor-binding domain antibodies and vaccine doses, Journal of the American Society of Nephrology (2022). DOI: 10.1681/asn.2022040504
American Society of Nephrology
Risk of SARS-CoV-2 infection during the omicron surge in patients on dialysis (2022, August 15)
retrieved 15 August 2022
This document is subject to copyright. Apart from any fair dealing for the purpose of private study or research, no
part may be reproduced without the written permission. The content is provided for information purposes only.